#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Diy_coref|
#T_RL=webanno.custom.Diy_coref_re|BT_webanno.custom.Diy_coref


#Text=[0073] The members of the group of DNA sequences can for example be various allelic variants of a human gene.
1-1	0-1	[	_	_	
1-2	1-5	0073	_	_	
1-3	5-6	]	_	_	
1-4	7-10	The	_	_	
1-5	11-18	members	_	_	
1-6	19-21	of	_	_	
1-7	22-25	the	_	_	
1-8	26-31	group	_	_	
1-9	32-34	of	_	_	
1-10	35-38	DNA	_	_	
1-11	39-48	sequences	_	_	
1-12	49-52	can	_	_	
1-13	53-56	for	_	_	
1-14	57-64	example	_	_	
1-15	65-67	be	_	_	
1-16	68-75	various	_	_	
1-17	76-83	allelic	_	_	
1-18	84-92	variants	_	_	
1-19	93-95	of	_	_	
1-20	96-97	a	_	_	
1-21	98-103	human	_	_	
1-22	104-108	gene	_	_	
1-23	108-109	.	_	_	

#Text=If for example the sequence of a particular human gene is examined, which in the relevant coding sequence has a single variable position at a known position, then theoretically in addition to the wild-type sequence, three further sequence variants are conceivable, each having a nucleotide with another base at this position.
2-1	110-112	If	_	_	
2-2	113-116	for	_	_	
2-3	117-124	example	_	_	
2-4	125-128	the	_	_	
2-5	129-137	sequence	_	_	
2-6	138-140	of	_	_	
2-7	141-142	a	_	_	
2-8	143-153	particular	_	_	
2-9	154-159	human	_	_	
2-10	160-164	gene	_	_	
2-11	165-167	is	_	_	
2-12	168-176	examined	_	_	
2-13	176-177	,	_	_	
2-14	178-183	which	_	_	
2-15	184-186	in	_	_	
2-16	187-190	the	_	_	
2-17	191-199	relevant	_	_	
2-18	200-206	coding	_	_	
2-19	207-215	sequence	_	_	
2-20	216-219	has	_	_	
2-21	220-221	a	_	_	
2-22	222-228	single	_	_	
2-23	229-237	variable	_	_	
2-24	238-246	position	_	_	
2-25	247-249	at	_	_	
2-26	250-251	a	_	_	
2-27	252-257	known	_	_	
2-28	258-266	position	_	_	
2-29	266-267	,	_	_	
2-30	268-272	then	_	_	
2-31	273-286	theoretically	_	_	
2-32	287-289	in	_	_	
2-33	290-298	addition	_	_	
2-34	299-301	to	_	_	
2-35	302-305	the	_	_	
2-36	306-315	wild-type	_	_	
2-37	316-324	sequence	_	_	
2-38	324-325	,	_	_	
2-39	326-331	three	_	_	
2-40	332-339	further	_	_	
2-41	340-348	sequence	_	_	
2-42	349-357	variants	_	_	
2-43	358-361	are	_	_	
2-44	362-373	conceivable	_	_	
2-45	373-374	,	_	_	
2-46	375-379	each	_	_	
2-47	380-386	having	_	_	
2-48	387-388	a	_	_	
2-49	389-399	nucleotide	_	_	
2-50	400-404	with	_	_	
2-51	405-412	another	_	_	
2-52	413-417	base	_	_	
2-53	418-420	at	_	_	
2-54	421-425	this	_	_	
2-55	426-434	position	_	_	
2-56	434-435	.	_	_	

#Text=This means that the target DNA sequence and the three variant sequences form a group, the members of which each differ exactly at one predetermined nucleotide position from the other members of the group.
#Text=[0074] Again, cells that are provided on a support, wherein at least a portion of the cells is lysed, so that the DNA has been released from the cells and adheres to the support, serve as the starting point of the method.
3-1	436-440	This	_	_	
3-2	441-446	means	_	_	
3-3	447-451	that	_	_	
3-4	452-455	the	_	_	
3-5	456-462	target	_	_	
3-6	463-466	DNA	_	_	
3-7	467-475	sequence	_	_	
3-8	476-479	and	_	_	
3-9	480-483	the	_	_	
3-10	484-489	three	_	_	
3-11	490-497	variant	_	_	
3-12	498-507	sequences	_	_	
3-13	508-512	form	_	_	
3-14	513-514	a	_	_	
3-15	515-520	group	_	_	
3-16	520-521	,	_	_	
3-17	522-525	the	_	_	
3-18	526-533	members	_	_	
3-19	534-536	of	_	_	
3-20	537-542	which	_	_	
3-21	543-547	each	_	_	
3-22	548-554	differ	_	_	
3-23	555-562	exactly	_	_	
3-24	563-565	at	_	_	
3-25	566-569	one	_	_	
3-26	570-583	predetermined	_	_	
3-27	584-594	nucleotide	_	_	
3-28	595-603	position	_	_	
3-29	604-608	from	_	_	
3-30	609-612	the	_	_	
3-31	613-618	other	_	_	
3-32	619-626	members	_	_	
3-33	627-629	of	_	_	
3-34	630-633	the	_	_	
3-35	634-639	group	_	_	
3-36	639-640	.	_	_	
3-37	641-642	[	_	_	
3-38	642-646	0074	_	_	
3-39	646-647	]	_	_	
3-40	648-653	Again	_	_	
3-41	653-654	,	_	_	
3-42	655-660	cells	_	_	
3-43	661-665	that	_	_	
3-44	666-669	are	_	_	
3-45	670-678	provided	_	_	
3-46	679-681	on	_	_	
3-47	682-683	a	_	_	
3-48	684-691	support	_	_	
3-49	691-692	,	_	_	
3-50	693-700	wherein	_	_	
3-51	701-703	at	_	_	
3-52	704-709	least	_	_	
3-53	710-711	a	_	_	
3-54	712-719	portion	_	_	
3-55	720-722	of	_	_	
3-56	723-726	the	_	_	
3-57	727-732	cells	_	_	
3-58	733-735	is	_	_	
3-59	736-741	lysed	_	_	
3-60	741-742	,	_	_	
3-61	743-745	so	_	_	
3-62	746-750	that	_	_	
3-63	751-754	the	_	_	
3-64	755-758	DNA	_	_	
3-65	759-762	has	_	_	
3-66	763-767	been	_	_	
3-67	768-776	released	_	_	
3-68	777-781	from	_	_	
3-69	782-785	the	_	_	
3-70	786-791	cells	_	_	
3-71	792-795	and	_	_	
3-72	796-803	adheres	_	_	
3-73	804-806	to	_	_	
3-74	807-810	the	_	_	
3-75	811-818	support	_	_	
3-76	818-819	,	_	_	
3-77	820-825	serve	_	_	
3-78	826-828	as	_	_	
3-79	829-832	the	_	_	
3-80	833-841	starting	_	_	
3-81	842-847	point	_	_	
3-82	848-850	of	_	_	
3-83	851-854	the	_	_	
3-84	855-861	method	_	_	
3-85	861-862	.	_	_	

#Text=Preferably the DNA is in single-stranded form.
4-1	863-873	Preferably	_	_	
4-2	874-877	the	_	_	
4-3	878-881	DNA	_	_	
4-4	882-884	is	_	_	
4-5	885-887	in	_	_	
4-6	888-903	single-stranded	_	_	
4-7	904-908	form	_	_	
4-8	908-909	.	_	_	

#Text=The cells are preferably obtained from a mammal, for example a human, and it does not matter which cells of the body are used for the method.
5-1	910-913	The	_	_	
5-2	914-919	cells	_	_	
5-3	920-923	are	_	_	
5-4	924-934	preferably	_	_	
5-5	935-943	obtained	_	_	
5-6	944-948	from	_	_	
5-7	949-950	a	_	_	
5-8	951-957	mammal	_	_	
5-9	957-958	,	_	_	
5-10	959-962	for	_	_	
5-11	963-970	example	_	_	
5-12	971-972	a	_	_	
5-13	973-978	human	_	_	
5-14	978-979	,	_	_	
5-15	980-983	and	_	_	
5-16	984-986	it	_	_	
5-17	987-991	does	_	_	
5-18	992-995	not	_	_	
5-19	996-1002	matter	_	_	
5-20	1003-1008	which	_	_	
5-21	1009-1014	cells	_	_	
5-22	1015-1017	of	_	_	
5-23	1018-1021	the	_	_	
5-24	1022-1026	body	_	_	
5-25	1027-1030	are	_	_	
5-26	1031-1035	used	_	_	
5-27	1036-1039	for	_	_	
5-28	1040-1043	the	_	_	
5-29	1044-1050	method	_	_	
5-30	1050-1051	.	_	_	

#Text=As it should be possible to detect the nucleotide to be identified (e.g. a single nucleotide polymorphism) in the genomic DNA of every cell of the mammal's body, cells that are particularly easy to lyse and/or can be obtained particularly easily can be selected for the method.
6-1	1052-1054	As	_	_	
6-2	1055-1057	it	_	_	
6-3	1058-1064	should	_	_	
6-4	1065-1067	be	_	_	
6-5	1068-1076	possible	_	_	
6-6	1077-1079	to	_	_	
6-7	1080-1086	detect	_	_	
6-8	1087-1090	the	_	_	
6-9	1091-1101	nucleotide	_	_	
6-10	1102-1104	to	_	_	
6-11	1105-1107	be	_	_	
6-12	1108-1118	identified	_	_	
6-13	1119-1120	(	_	_	
6-14	1120-1123	e.g	_	_	
6-15	1123-1124	.	_	_	
6-16	1125-1126	a	_	_	
6-17	1127-1133	single	_	_	
6-18	1134-1144	nucleotide	_	_	
6-19	1145-1157	polymorphism	_	_	
6-20	1157-1158	)	_	_	
6-21	1159-1161	in	_	_	
6-22	1162-1165	the	_	_	
6-23	1166-1173	genomic	_	_	
6-24	1174-1177	DNA	_	_	
6-25	1178-1180	of	_	_	
6-26	1181-1186	every	_	_	
6-27	1187-1191	cell	_	_	
6-28	1192-1194	of	_	_	
6-29	1195-1198	the	_	_	
6-30	1199-1207	mammal's	_	_	
6-31	1208-1212	body	_	_	
6-32	1212-1213	,	_	_	
6-33	1214-1219	cells	_	_	
6-34	1220-1224	that	_	_	
6-35	1225-1228	are	_	_	
6-36	1229-1241	particularly	_	_	
6-37	1242-1246	easy	_	_	
6-38	1247-1249	to	_	_	
6-39	1250-1254	lyse	_	_	
6-40	1255-1258	and	_	_	
6-41	1258-1259	/	_	_	
6-42	1259-1261	or	_	_	
6-43	1262-1265	can	_	_	
6-44	1266-1268	be	_	_	
6-45	1269-1277	obtained	_	_	
6-46	1278-1290	particularly	_	_	
6-47	1291-1297	easily	_	_	
6-48	1298-1301	can	_	_	
6-49	1302-1304	be	_	_	
6-50	1305-1313	selected	_	_	
6-51	1314-1317	for	_	_	
6-52	1318-1321	the	_	_	
6-53	1322-1328	method	_	_	
6-54	1328-1329	.	_	_	

#Text=The cells can be mucosal cells, preferably human mucosal cells.
7-1	1330-1333	The	_	_	
7-2	1334-1339	cells	_	_	
7-3	1340-1343	can	_	_	
7-4	1344-1346	be	_	_	
7-5	1347-1354	mucosal	_	_	
7-6	1355-1360	cells	_	_	
7-7	1360-1361	,	_	_	
7-8	1362-1372	preferably	_	_	
7-9	1373-1378	human	_	_	
7-10	1379-1386	mucosal	_	_	
7-11	1387-1392	cells	_	_	
7-12	1392-1393	.	_	_	

#Text=Human oral mucosal cells are particularly preferred.
8-1	1394-1399	Human	_	_	
8-2	1400-1404	oral	_	_	
8-3	1405-1412	mucosal	_	_	
8-4	1413-1418	cells	_	_	
8-5	1419-1422	are	_	_	
8-6	1423-1435	particularly	_	_	
8-7	1436-1445	preferred	_	_	
8-8	1445-1446	.	_	_	

#Text=The materials described above can be considered as the support, and the use of "Omni-Swab" brushes or comparable products is particularly preferred.
#Text=[0075] The cells provided on the support are contacted with a first and a second oligonucleotide, wherein at least one is labeled with a beta-D-galactopyranoside, which on hydrolysis of the glycosidic bond forms a water-insoluble dye.
9-1	1447-1450	The	_	_	
9-2	1451-1460	materials	_	_	
9-3	1461-1470	described	_	_	
9-4	1471-1476	above	_	_	
9-5	1477-1480	can	_	_	
9-6	1481-1483	be	_	_	
9-7	1484-1494	considered	_	_	
9-8	1495-1497	as	_	_	
9-9	1498-1501	the	_	_	
9-10	1502-1509	support	_	_	
9-11	1509-1510	,	_	_	
9-12	1511-1514	and	_	_	
9-13	1515-1518	the	_	_	
9-14	1519-1522	use	_	_	
9-15	1523-1525	of	_	_	
9-16	1526-1527	"	_	_	
9-17	1527-1536	Omni-Swab	_	_	
9-18	1536-1537	"	_	_	
9-19	1538-1545	brushes	_	_	
9-20	1546-1548	or	_	_	
9-21	1549-1559	comparable	_	_	
9-22	1560-1568	products	_	_	
9-23	1569-1571	is	_	_	
9-24	1572-1584	particularly	_	_	
9-25	1585-1594	preferred	_	_	
9-26	1594-1595	.	_	_	
9-27	1596-1597	[	*[1]	12-8[2_1]	
9-28	1597-1601	0075	*[1]	_	
9-29	1601-1602	]	*[1]	_	
9-30	1603-1606	The	*[1]	_	
9-31	1607-1612	cells	*[1]	_	
9-32	1613-1621	provided	*[1]	_	
9-33	1622-1624	on	*[1]	_	
9-34	1625-1628	the	*[1]	_	
9-35	1629-1636	support	*[1]	_	
9-36	1637-1640	are	*[1]	_	
9-37	1641-1650	contacted	*[1]	_	
9-38	1651-1655	with	*[1]	_	
9-39	1656-1657	a	*[1]	_	
9-40	1658-1663	first	*[1]	_	
9-41	1664-1667	and	*[1]	_	
9-42	1668-1669	a	*[1]	_	
9-43	1670-1676	second	*[1]	_	
9-44	1677-1692	oligonucleotide	*[1]	_	
9-45	1692-1693	,	*[1]	_	
9-46	1694-1701	wherein	*[1]	_	
9-47	1702-1704	at	*[1]	_	
9-48	1705-1710	least	*[1]	_	
9-49	1711-1714	one	*[1]	_	
9-50	1715-1717	is	*[1]	_	
9-51	1718-1725	labeled	*[1]	_	
9-52	1726-1730	with	*[1]	_	
9-53	1731-1732	a	*[1]	_	
9-54	1733-1757	beta-D-galactopyranoside	*[1]	_	
9-55	1757-1758	,	*[1]	_	
9-56	1759-1764	which	*[1]	_	
9-57	1765-1767	on	*[1]	_	
9-58	1768-1778	hydrolysis	*[1]	_	
9-59	1779-1781	of	*[1]	_	
9-60	1782-1785	the	*[1]	_	
9-61	1786-1796	glycosidic	*[1]	_	
9-62	1797-1801	bond	*[1]	_	
9-63	1802-1807	forms	*[1]	_	
9-64	1808-1809	a	*[1]	_	
9-65	1810-1825	water-insoluble	*[1]	_	
9-66	1826-1829	dye	*[1]	_	
9-67	1829-1830	.	*[1]	_	

#Text=It is equally possible, however, to label both oligonucleotides with the same beta-D-galactopyranoside or with different beta-D-galactopyranosides.
10-1	1831-1833	It	_	_	
10-2	1834-1836	is	_	_	
10-3	1837-1844	equally	_	_	
10-4	1845-1853	possible	_	_	
10-5	1853-1854	,	_	_	
10-6	1855-1862	however	_	_	
10-7	1862-1863	,	_	_	
10-8	1864-1866	to	_	_	
10-9	1867-1872	label	_	_	
10-10	1873-1877	both	_	_	
10-11	1878-1894	oligonucleotides	_	_	
10-12	1895-1899	with	_	_	
10-13	1900-1903	the	_	_	
10-14	1904-1908	same	_	_	
10-15	1909-1933	beta-D-galactopyranoside	_	_	
10-16	1934-1936	or	_	_	
10-17	1937-1941	with	_	_	
10-18	1942-1951	different	_	_	
10-19	1952-1977	beta-D-galactopyranosides	_	_	
10-20	1977-1978	.	_	_	

#Text=This leads, because of the higher number of markers, to intensification of the signal.
11-1	1979-1983	This	_	_	
11-2	1984-1989	leads	_	_	
11-3	1989-1990	,	_	_	
11-4	1991-1998	because	_	_	
11-5	1999-2001	of	_	_	
11-6	2002-2005	the	_	_	
11-7	2006-2012	higher	_	_	
11-8	2013-2019	number	_	_	
11-9	2020-2022	of	_	_	
11-10	2023-2030	markers	_	_	
11-11	2030-2031	,	_	_	
11-12	2032-2034	to	_	_	
11-13	2035-2050	intensification	_	_	
11-14	2051-2053	of	_	_	
11-15	2054-2057	the	_	_	
11-16	2058-2064	signal	_	_	
11-17	2064-2065	.	_	_	

#Text=The beta-D-galactopyranosides that can be used in this method were described above.
12-1	2066-2069	The	_	_	
12-2	2070-2095	beta-D-galactopyranosides	_	_	
12-3	2096-2100	that	_	_	
12-4	2101-2104	can	_	_	
12-5	2105-2107	be	_	_	
12-6	2108-2112	used	_	_	
12-7	2113-2115	in	_	_	
12-8	2116-2120	this	*[2]	_	
12-9	2121-2127	method	*[2]	_	
12-10	2128-2132	were	_	_	
12-11	2133-2142	described	_	_	
12-12	2143-2148	above	_	_	
12-13	2148-2149	.	_	_	

#Text=According to a preferred embodiment the beta-D-galactopyranoside is selected from the group comprising 5-bromo-4-chloro-3-indoxyl-beta-D-galactopyranoside (x-Gal), N-methylindolyl-beta-D-galactopyranoside, 5-iodo-3-indolyl-beta-D-galactopyranoside, 5-bromo-6-chloro-3-indolyl-beta-D-galactopyranoside, 6-chloro-3-indoxyl-beta-D-galactopyranoside, para-naphtholbenzein-beta-D-galactopyranoside, cyclohexenoesculetin-beta-D-galactopyranoside and 8-hydroxy-quinoline-beta-D-galactopyranoside.
13-1	2150-2159	According	_	_	
13-2	2160-2162	to	_	_	
13-3	2163-2164	a	_	_	
13-4	2165-2174	preferred	_	_	
13-5	2175-2185	embodiment	_	_	
13-6	2186-2189	the	_	_	
13-7	2190-2214	beta-D-galactopyranoside	_	_	
13-8	2215-2217	is	_	_	
13-9	2218-2226	selected	_	_	
13-10	2227-2231	from	_	_	
13-11	2232-2235	the	_	_	
13-12	2236-2241	group	_	_	
13-13	2242-2252	comprising	_	_	
13-14	2253-2254	5	_	_	
13-15	2254-2255	-	_	_	
13-16	2255-2260	bromo	_	_	
13-17	2260-2261	-	_	_	
13-18	2261-2262	4	_	_	
13-19	2262-2263	-	_	_	
13-20	2263-2269	chloro	_	_	
13-21	2269-2270	-	_	_	
13-22	2270-2271	3	_	_	
13-23	2271-2272	-	_	_	
13-24	2272-2304	indoxyl-beta-D-galactopyranoside	_	_	
13-25	2305-2306	(	_	_	
13-26	2306-2311	x-Gal	_	_	
13-27	2311-2312	)	_	_	
13-28	2312-2313	,	_	_	
13-29	2314-2354	N-methylindolyl-beta-D-galactopyranoside	_	_	
13-30	2354-2355	,	_	_	
13-31	2356-2357	5	_	_	
13-32	2357-2358	-	_	_	
13-33	2358-2362	iodo	_	_	
13-34	2362-2363	-	_	_	
13-35	2363-2364	3	_	_	
13-36	2364-2365	-	_	_	
13-37	2365-2397	indolyl-beta-D-galactopyranoside	_	_	
13-38	2397-2398	,	_	_	
13-39	2399-2400	5	_	_	
13-40	2400-2401	-	_	_	
13-41	2401-2406	bromo	_	_	
13-42	2406-2407	-	_	_	
13-43	2407-2408	6	_	_	
13-44	2408-2409	-	_	_	
13-45	2409-2415	chloro	_	_	
13-46	2415-2416	-	_	_	
13-47	2416-2417	3	_	_	
13-48	2417-2418	-	_	_	
13-49	2418-2450	indolyl-beta-D-galactopyranoside	_	_	
13-50	2450-2451	,	_	_	
13-51	2452-2453	6	_	_	
13-52	2453-2454	-	_	_	
13-53	2454-2460	chloro	_	_	
13-54	2460-2461	-	_	_	
13-55	2461-2462	3	_	_	
13-56	2462-2463	-	_	_	
13-57	2463-2495	indoxyl-beta-D-galactopyranoside	_	_	
13-58	2495-2496	,	_	_	
13-59	2497-2542	para-naphtholbenzein-beta-D-galactopyranoside	_	_	
13-60	2542-2543	,	_	_	
13-61	2544-2589	cyclohexenoesculetin-beta-D-galactopyranoside	_	_	
13-62	2590-2593	and	_	_	
13-63	2594-2595	8	_	_	
13-64	2595-2596	-	_	_	
13-65	2596-2638	hydroxy-quinoline-beta-D-galactopyranoside	_	_	
13-66	2638-2639	.	_	_	

#Text=According to an especially preferred embodiment the beta-D-galactopyranoside is 5-bromo-4-chloro-3-indoxyl-beta-D-galactopyranoside (x-Gal).
#Text=[0076] The oligonucleotides are selected so that in each case they can hybridize with a terminal segment to the target DNA sequence.
14-1	2640-2649	According	_	_	
14-2	2650-2652	to	_	_	
14-3	2653-2655	an	_	_	
14-4	2656-2666	especially	_	_	
14-5	2667-2676	preferred	_	_	
14-6	2677-2687	embodiment	_	_	
14-7	2688-2691	the	_	_	
14-8	2692-2716	beta-D-galactopyranoside	_	_	
14-9	2717-2719	is	_	_	
14-10	2720-2721	5	_	_	
14-11	2721-2722	-	_	_	
14-12	2722-2727	bromo	_	_	
14-13	2727-2728	-	_	_	
14-14	2728-2729	4	_	_	
14-15	2729-2730	-	_	_	
14-16	2730-2736	chloro	_	_	
14-17	2736-2737	-	_	_	
14-18	2737-2738	3	_	_	
14-19	2738-2739	-	_	_	
14-20	2739-2771	indoxyl-beta-D-galactopyranoside	_	_	
14-21	2772-2773	(	_	_	
14-22	2773-2778	x-Gal	_	_	
14-23	2778-2779	)	_	_	
14-24	2779-2780	.	_	_	
14-25	2781-2782	[	_	_	
14-26	2782-2786	0076	_	_	
14-27	2786-2787	]	_	_	
14-28	2788-2791	The	_	_	
14-29	2792-2808	oligonucleotides	_	_	
14-30	2809-2812	are	_	_	
14-31	2813-2821	selected	_	_	
14-32	2822-2824	so	_	_	
14-33	2825-2829	that	_	_	
14-34	2830-2832	in	_	_	
14-35	2833-2837	each	_	_	
14-36	2838-2842	case	_	_	
14-37	2843-2847	they	_	_	
14-38	2848-2851	can	_	_	
14-39	2852-2861	hybridize	_	_	
14-40	2862-2866	with	_	_	
14-41	2867-2868	a	_	_	
14-42	2869-2877	terminal	_	_	
14-43	2878-2885	segment	_	_	
14-44	2886-2888	to	_	_	
14-45	2889-2892	the	_	_	
14-46	2893-2899	target	_	_	
14-47	2900-2903	DNA	_	_	
14-48	2904-2912	sequence	_	_	
14-49	2912-2913	.	_	_	

#Text=This means that each of the two oligonucleotides has at least one terminal segment that is sufficiently complementary to a corresponding segment of the target DNA sequence to make hybridization to the target DNA sequence possible.
15-1	2914-2918	This	_	_	
15-2	2919-2924	means	_	_	
15-3	2925-2929	that	_	_	
15-4	2930-2934	each	_	_	
15-5	2935-2937	of	_	_	
15-6	2938-2941	the	_	_	
15-7	2942-2945	two	_	_	
15-8	2946-2962	oligonucleotides	_	_	
15-9	2963-2966	has	_	_	
15-10	2967-2969	at	_	_	
15-11	2970-2975	least	_	_	
15-12	2976-2979	one	_	_	
15-13	2980-2988	terminal	_	_	
15-14	2989-2996	segment	_	_	
15-15	2997-3001	that	_	_	
15-16	3002-3004	is	_	_	
15-17	3005-3017	sufficiently	_	_	
15-18	3018-3031	complementary	_	_	
15-19	3032-3034	to	_	_	
15-20	3035-3036	a	_	_	
15-21	3037-3050	corresponding	_	_	
15-22	3051-3058	segment	_	_	
15-23	3059-3061	of	_	_	
15-24	3062-3065	the	_	_	
15-25	3066-3072	target	_	_	
15-26	3073-3076	DNA	_	_	
15-27	3077-3085	sequence	_	_	
15-28	3086-3088	to	_	_	
15-29	3089-3093	make	_	_	
15-30	3094-3107	hybridization	_	_	
15-31	3108-3110	to	_	_	
15-32	3111-3114	the	_	_	
15-33	3115-3121	target	_	_	
15-34	3122-3125	DNA	_	_	
15-35	3126-3134	sequence	_	_	
15-36	3135-3143	possible	_	_	
15-37	3143-3144	.	_	_	

#Text=Preferably the segment allows a specific hybridization, i.e. hybridization only to the intended segment of the target DNA sequence and not to other sequences that have little or no similarity with the target DNA sequence.
16-1	3145-3155	Preferably	_	_	
16-2	3156-3159	the	_	_	
16-3	3160-3167	segment	_	_	
16-4	3168-3174	allows	_	_	
16-5	3175-3176	a	_	_	
16-6	3177-3185	specific	_	_	
16-7	3186-3199	hybridization	_	_	
16-8	3199-3200	,	_	_	
16-9	3201-3204	i.e	_	_	
16-10	3204-3205	.	_	_	
16-11	3206-3219	hybridization	_	_	
16-12	3220-3224	only	_	_	
16-13	3225-3227	to	_	_	
16-14	3228-3231	the	_	_	
16-15	3232-3240	intended	_	_	
16-16	3241-3248	segment	_	_	
16-17	3249-3251	of	_	_	
16-18	3252-3255	the	_	_	
16-19	3256-3262	target	_	_	
16-20	3263-3266	DNA	_	_	
16-21	3267-3275	sequence	_	_	
16-22	3276-3279	and	_	_	
16-23	3280-3283	not	_	_	
16-24	3284-3286	to	_	_	
16-25	3287-3292	other	_	_	
16-26	3293-3302	sequences	_	_	
16-27	3303-3307	that	_	_	
16-28	3308-3312	have	_	_	
16-29	3313-3319	little	_	_	
16-30	3320-3322	or	_	_	
16-31	3323-3325	no	_	_	
16-32	3326-3336	similarity	_	_	
16-33	3337-3341	with	_	_	
16-34	3342-3345	the	_	_	
16-35	3346-3352	target	_	_	
16-36	3353-3356	DNA	_	_	
16-37	3357-3365	sequence	_	_	
16-38	3365-3366	.	_	_	

#Text=The segment complementary to the target DNA sequence is terminal, i.e. it comprises a terminus (either the 5'-terminus or the 3'-terminus) of the respective oligonucleotide and extends in the direction of the opposite terminus of the same oligonucleotide.
17-1	3367-3370	The	_	_	
17-2	3371-3378	segment	_	_	
17-3	3379-3392	complementary	_	_	
17-4	3393-3395	to	_	_	
17-5	3396-3399	the	_	_	
17-6	3400-3406	target	_	_	
17-7	3407-3410	DNA	_	_	
17-8	3411-3419	sequence	_	_	
17-9	3420-3422	is	_	_	
17-10	3423-3431	terminal	_	_	
17-11	3431-3432	,	_	_	
17-12	3433-3436	i.e	_	_	
17-13	3436-3437	.	_	_	
17-14	3438-3440	it	_	_	
17-15	3441-3450	comprises	_	_	
17-16	3451-3452	a	_	_	
17-17	3453-3461	terminus	_	_	
17-18	3462-3463	(	_	_	
17-19	3463-3469	either	_	_	
17-20	3470-3473	the	_	_	
17-21	3474-3475	5	_	_	
17-22	3475-3476	'	_	_	
17-23	3476-3477	-	_	_	
17-24	3477-3485	terminus	_	_	
17-25	3486-3488	or	_	_	
17-26	3489-3492	the	_	_	
17-27	3493-3494	3	_	_	
17-28	3494-3495	'	_	_	
17-29	3495-3496	-	_	_	
17-30	3496-3504	terminus	_	_	
17-31	3504-3505	)	_	_	
17-32	3506-3508	of	_	_	
17-33	3509-3512	the	_	_	
17-34	3513-3523	respective	_	_	
17-35	3524-3539	oligonucleotide	_	_	
17-36	3540-3543	and	_	_	
17-37	3544-3551	extends	_	_	
17-38	3552-3554	in	_	_	
17-39	3555-3558	the	_	_	
17-40	3559-3568	direction	_	_	
17-41	3569-3571	of	_	_	
17-42	3572-3575	the	_	_	
17-43	3576-3584	opposite	_	_	
17-44	3585-3593	terminus	_	_	
17-45	3594-3596	of	_	_	
17-46	3597-3600	the	_	_	
17-47	3601-3605	same	_	_	
17-48	3606-3621	oligonucleotide	_	_	
17-49	3621-3622	.	_	_	

#Text=It is preferred that the terminal segment of the oligonucleotides necessary for hybridization to the target sequence has a length of at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 22, 24, 26, 28, 30, 40, 50 or more nucleotides.
18-1	3623-3625	It	_	_	
18-2	3626-3628	is	_	_	
18-3	3629-3638	preferred	_	_	
18-4	3639-3643	that	_	_	
18-5	3644-3647	the	_	_	
18-6	3648-3656	terminal	_	_	
18-7	3657-3664	segment	_	_	
18-8	3665-3667	of	_	_	
18-9	3668-3671	the	_	_	
18-10	3672-3688	oligonucleotides	_	_	
18-11	3689-3698	necessary	_	_	
18-12	3699-3702	for	_	_	
18-13	3703-3716	hybridization	_	_	
18-14	3717-3719	to	_	_	
18-15	3720-3723	the	_	_	
18-16	3724-3730	target	_	_	
18-17	3731-3739	sequence	_	_	
18-18	3740-3743	has	_	_	
18-19	3744-3745	a	_	_	
18-20	3746-3752	length	_	_	
18-21	3753-3755	of	_	_	
18-22	3756-3758	at	_	_	
18-23	3759-3764	least	_	_	
18-24	3765-3766	5	_	_	
18-25	3766-3767	,	_	_	
18-26	3768-3769	6	_	_	
18-27	3769-3770	,	_	_	
18-28	3771-3772	7	_	_	
18-29	3772-3773	,	_	_	
18-30	3774-3775	8	_	_	
18-31	3775-3776	,	_	_	
18-32	3777-3778	9	_	_	
18-33	3778-3779	,	_	_	
18-34	3780-3782	10	_	_	
18-35	3782-3783	,	_	_	
18-36	3784-3786	11	_	_	
18-37	3786-3787	,	_	_	
18-38	3788-3790	12	_	_	
18-39	3790-3791	,	_	_	
18-40	3792-3794	13	_	_	
18-41	3794-3795	,	_	_	
18-42	3796-3798	14	_	_	
18-43	3798-3799	,	_	_	
18-44	3800-3802	15	_	_	
18-45	3802-3803	,	_	_	
18-46	3804-3806	16	_	_	
18-47	3806-3807	,	_	_	
18-48	3808-3810	17	_	_	
18-49	3810-3811	,	_	_	
18-50	3812-3814	18	_	_	
18-51	3814-3815	,	_	_	
18-52	3816-3818	19	_	_	
18-53	3818-3819	,	_	_	
18-54	3820-3822	20	_	_	
18-55	3822-3823	,	_	_	
18-56	3824-3826	22	_	_	
18-57	3826-3827	,	_	_	
18-58	3828-3830	24	_	_	
18-59	3830-3831	,	_	_	
18-60	3832-3834	26	_	_	
18-61	3834-3835	,	_	_	
18-62	3836-3838	28	_	_	
18-63	3838-3839	,	_	_	
18-64	3840-3842	30	_	_	
18-65	3842-3843	,	_	_	
18-66	3844-3846	40	_	_	
18-67	3846-3847	,	_	_	
18-68	3848-3850	50	_	_	
18-69	3851-3853	or	_	_	
18-70	3854-3858	more	_	_	
18-71	3859-3870	nucleotides	_	_	
18-72	3870-3871	.	_	_	

#Text=It is not absolutely necessary for every nucleotide in this segment to be complementary to the corresponding nucleotide in the target DNA sequence, provided the segment is on the whole sufficiently complementary to be able to hybridize with a sufficiently high specificity to the predetermined segment of the target DNA sequence.
19-1	3872-3874	It	_	_	
19-2	3875-3877	is	_	_	
19-3	3878-3881	not	_	_	
19-4	3882-3892	absolutely	_	_	
19-5	3893-3902	necessary	_	_	
19-6	3903-3906	for	_	_	
19-7	3907-3912	every	_	_	
19-8	3913-3923	nucleotide	_	_	
19-9	3924-3926	in	_	_	
19-10	3927-3931	this	_	_	
19-11	3932-3939	segment	_	_	
19-12	3940-3942	to	_	_	
19-13	3943-3945	be	_	_	
19-14	3946-3959	complementary	_	_	
19-15	3960-3962	to	_	_	
19-16	3963-3966	the	_	_	
19-17	3967-3980	corresponding	_	_	
19-18	3981-3991	nucleotide	_	_	
19-19	3992-3994	in	_	_	
19-20	3995-3998	the	_	_	
19-21	3999-4005	target	_	_	
19-22	4006-4009	DNA	_	_	
19-23	4010-4018	sequence	_	_	
19-24	4018-4019	,	_	_	
19-25	4020-4028	provided	_	_	
19-26	4029-4032	the	_	_	
19-27	4033-4040	segment	_	_	
19-28	4041-4043	is	_	_	
19-29	4044-4046	on	_	_	
19-30	4047-4050	the	_	_	
19-31	4051-4056	whole	_	_	
19-32	4057-4069	sufficiently	_	_	
19-33	4070-4083	complementary	_	_	
19-34	4084-4086	to	_	_	
19-35	4087-4089	be	_	_	
19-36	4090-4094	able	_	_	
19-37	4095-4097	to	_	_	
19-38	4098-4107	hybridize	_	_	
19-39	4108-4112	with	_	_	
19-40	4113-4114	a	_	_	
19-41	4115-4127	sufficiently	_	_	
19-42	4128-4132	high	_	_	
19-43	4133-4144	specificity	_	_	
19-44	4145-4147	to	_	_	
19-45	4148-4151	the	_	_	
19-46	4152-4165	predetermined	_	_	
19-47	4166-4173	segment	_	_	
19-48	4174-4176	of	_	_	
19-49	4177-4180	the	_	_	
19-50	4181-4187	target	_	_	
19-51	4188-4191	DNA	_	_	
19-52	4192-4200	sequence	_	_	
19-53	4200-4201	.	_	_	

#Text=It is preferred that the terminal segment of the oligonucleotides has a complete complementarity to a corresponding region of the target DNA sequence.
20-1	4202-4204	It	_	_	
20-2	4205-4207	is	_	_	
20-3	4208-4217	preferred	_	_	
20-4	4218-4222	that	_	_	
20-5	4223-4226	the	_	_	
20-6	4227-4235	terminal	_	_	
20-7	4236-4243	segment	_	_	
20-8	4244-4246	of	_	_	
20-9	4247-4250	the	_	_	
20-10	4251-4267	oligonucleotides	_	_	
20-11	4268-4271	has	_	_	
20-12	4272-4273	a	_	_	
20-13	4274-4282	complete	_	_	
20-14	4283-4298	complementarity	_	_	
20-15	4299-4301	to	_	_	
20-16	4302-4303	a	_	_	
20-17	4304-4317	corresponding	_	_	
20-18	4318-4324	region	_	_	
20-19	4325-4327	of	_	_	
20-20	4328-4331	the	_	_	
20-21	4332-4338	target	_	_	
20-22	4339-4342	DNA	_	_	
20-23	4343-4351	sequence	_	_	
20-24	4351-4352	.	_	_	

#Text=Of course, oligonucleotides that are completely complementary to the target DNA sequence can also be used according to the invention.
21-1	4353-4355	Of	_	_	
21-2	4356-4362	course	_	_	
21-3	4362-4363	,	_	_	
21-4	4364-4380	oligonucleotides	_	_	
21-5	4381-4385	that	_	_	
21-6	4386-4389	are	_	_	
21-7	4390-4400	completely	_	_	
21-8	4401-4414	complementary	_	_	
21-9	4415-4417	to	_	_	
21-10	4418-4421	the	_	_	
21-11	4422-4428	target	_	_	
21-12	4429-4432	DNA	_	_	
21-13	4433-4441	sequence	_	_	
21-14	4442-4445	can	_	_	
21-15	4446-4450	also	_	_	
21-16	4451-4453	be	_	_	
21-17	4454-4458	used	_	_	
21-18	4459-4468	according	_	_	
21-19	4469-4471	to	_	_	
21-20	4472-4475	the	_	_	
21-21	4476-4485	invention	_	_	
21-22	4485-4486	.	_	_	

#Text=According to a particularly preferred embodiment, therefore, the first and/or second oligonucleotide is complementary over its entire length to the target DNA sequence.
22-1	4487-4496	According	_	_	
22-2	4497-4499	to	_	_	
22-3	4500-4501	a	_	_	
22-4	4502-4514	particularly	_	_	
22-5	4515-4524	preferred	_	_	
22-6	4525-4535	embodiment	_	_	
22-7	4535-4536	,	_	_	
22-8	4537-4546	therefore	_	_	
22-9	4546-4547	,	_	_	
22-10	4548-4551	the	_	_	
22-11	4552-4557	first	_	_	
22-12	4558-4561	and	_	_	
22-13	4561-4562	/	_	_	
22-14	4562-4564	or	_	_	
22-15	4565-4571	second	_	_	
22-16	4572-4587	oligonucleotide	_	_	
22-17	4588-4590	is	_	_	
22-18	4591-4604	complementary	_	_	
22-19	4605-4609	over	_	_	
22-20	4610-4613	its	_	_	
22-21	4614-4620	entire	_	_	
22-22	4621-4627	length	_	_	
22-23	4628-4630	to	_	_	
22-24	4631-4634	the	_	_	
22-25	4635-4641	target	_	_	
22-26	4642-4645	DNA	_	_	
22-27	4646-4654	sequence	_	_	
22-28	4654-4655	.	_	_	

#Text=If the oligonucleotides have segments that have no complementarity to the target sequence (e.g. as shown in FIG. 1), these segments can be used for labeling with the beta-D-galactopyranoside.
23-1	4656-4658	If	_	_	
23-2	4659-4662	the	_	_	
23-3	4663-4679	oligonucleotides	_	_	
23-4	4680-4684	have	_	_	
23-5	4685-4693	segments	_	_	
23-6	4694-4698	that	_	_	
23-7	4699-4703	have	_	_	
23-8	4704-4706	no	_	_	
23-9	4707-4722	complementarity	_	_	
23-10	4723-4725	to	_	_	
23-11	4726-4729	the	_	_	
23-12	4730-4736	target	_	_	
23-13	4737-4745	sequence	_	_	
23-14	4746-4747	(	_	_	
23-15	4747-4750	e.g	_	_	
23-16	4750-4751	.	_	_	
23-17	4752-4754	as	_	_	
23-18	4755-4760	shown	_	_	
23-19	4761-4763	in	_	_	
23-20	4764-4767	FIG	_	_	
23-21	4767-4768	.	_	_	
23-22	4769-4770	1	_	_	
23-23	4770-4771	)	_	_	
23-24	4771-4772	,	_	_	
23-25	4773-4778	these	_	_	
23-26	4779-4787	segments	_	_	
23-27	4788-4791	can	_	_	
23-28	4792-4794	be	_	_	
23-29	4795-4799	used	_	_	
23-30	4800-4803	for	_	_	
23-31	4804-4812	labeling	_	_	
23-32	4813-4817	with	_	_	
23-33	4818-4821	the	_	_	
23-34	4822-4846	beta-D-galactopyranoside	_	_	
23-35	4846-4847	.	_	_	

#Text=Labeling can, however, also take place at any other positions of the oligonucleotides.
#Text=[0077] The terminal segments of the first and second oligonucleotide hybridize immediately next to one another to the target DNA sequence, i.e. after hybridization of the terminal segments to the target DNA sequence, the two terminal nucleotides of the terminal segments are arranged immediately adjacent to one another.
24-1	4848-4856	Labeling	_	_	
24-2	4857-4860	can	_	_	
24-3	4860-4861	,	_	_	
24-4	4862-4869	however	_	_	
24-5	4869-4870	,	_	_	
24-6	4871-4875	also	_	_	
24-7	4876-4880	take	_	_	
24-8	4881-4886	place	_	_	
24-9	4887-4889	at	_	_	
24-10	4890-4893	any	_	_	
24-11	4894-4899	other	_	_	
24-12	4900-4909	positions	_	_	
24-13	4910-4912	of	_	_	
24-14	4913-4916	the	_	_	
24-15	4917-4933	oligonucleotides	_	_	
24-16	4933-4934	.	_	_	
24-17	4935-4936	[	_	_	
24-18	4936-4940	0077	_	_	
24-19	4940-4941	]	_	_	
24-20	4942-4945	The	_	_	
24-21	4946-4954	terminal	_	_	
24-22	4955-4963	segments	_	_	
24-23	4964-4966	of	_	_	
24-24	4967-4970	the	_	_	
24-25	4971-4976	first	_	_	
24-26	4977-4980	and	_	_	
24-27	4981-4987	second	_	_	
24-28	4988-5003	oligonucleotide	_	_	
24-29	5004-5013	hybridize	_	_	
24-30	5014-5025	immediately	_	_	
24-31	5026-5030	next	_	_	
24-32	5031-5033	to	_	_	
24-33	5034-5037	one	_	_	
24-34	5038-5045	another	_	_	
24-35	5046-5048	to	_	_	
24-36	5049-5052	the	_	_	
24-37	5053-5059	target	_	_	
24-38	5060-5063	DNA	_	_	
24-39	5064-5072	sequence	_	_	
24-40	5072-5073	,	_	_	
24-41	5074-5077	i.e	_	_	
24-42	5077-5078	.	_	_	
24-43	5079-5084	after	_	_	
24-44	5085-5098	hybridization	_	_	
24-45	5099-5101	of	_	_	
24-46	5102-5105	the	_	_	
24-47	5106-5114	terminal	_	_	
24-48	5115-5123	segments	_	_	
24-49	5124-5126	to	_	_	
24-50	5127-5130	the	_	_	
24-51	5131-5137	target	_	_	
24-52	5138-5141	DNA	_	_	
24-53	5142-5150	sequence	_	_	
24-54	5150-5151	,	_	_	
24-55	5152-5155	the	_	_	
24-56	5156-5159	two	_	_	
24-57	5160-5168	terminal	_	_	
24-58	5169-5180	nucleotides	_	_	
24-59	5181-5183	of	_	_	
24-60	5184-5187	the	_	_	
24-61	5188-5196	terminal	_	_	
24-62	5197-5205	segments	_	_	
24-63	5206-5209	are	_	_	
24-64	5210-5218	arranged	_	_	
24-65	5219-5230	immediately	_	_	
24-66	5231-5239	adjacent	_	_	
24-67	5240-5242	to	_	_	
24-68	5243-5246	one	_	_	
24-69	5247-5254	another	_	_	
24-70	5254-5255	.	_	_	

#Text=The terminal nucleotides of the terminal segments are arranged immediately adjacent to one another if they hybridize to two immediately adjacent nucleotides in the target DNA sequence.
25-1	5256-5259	The	_	_	
25-2	5260-5268	terminal	_	_	
25-3	5269-5280	nucleotides	_	_	
25-4	5281-5283	of	_	_	
25-5	5284-5287	the	_	_	
25-6	5288-5296	terminal	_	_	
25-7	5297-5305	segments	_	_	
25-8	5306-5309	are	_	_	
25-9	5310-5318	arranged	_	_	
25-10	5319-5330	immediately	_	_	
25-11	5331-5339	adjacent	_	_	
25-12	5340-5342	to	_	_	
25-13	5343-5346	one	_	_	
25-14	5347-5354	another	_	_	
25-15	5355-5357	if	_	_	
25-16	5358-5362	they	_	_	
25-17	5363-5372	hybridize	_	_	
25-18	5373-5375	to	_	_	
25-19	5376-5379	two	_	_	
25-20	5380-5391	immediately	_	_	
25-21	5392-5400	adjacent	_	_	
25-22	5401-5412	nucleotides	_	_	
25-23	5413-5415	in	_	_	
25-24	5416-5419	the	_	_	
25-25	5420-5426	target	_	_	
25-26	5427-5430	DNA	_	_	
25-27	5431-5439	sequence	_	_	
25-28	5439-5440	.	_	_	

#Text=Hybridization of the two terminal nucleotides of the terminal segments to respective complementary nucleotides in the target DNA sequence is a necessary precondition for the subsequent linkage of the two oligonucleotides to form a ligation product.
26-1	5441-5454	Hybridization	_	_	
26-2	5455-5457	of	_	_	
26-3	5458-5461	the	_	_	
26-4	5462-5465	two	_	_	
26-5	5466-5474	terminal	_	_	
26-6	5475-5486	nucleotides	_	_	
26-7	5487-5489	of	_	_	
26-8	5490-5493	the	_	_	
26-9	5494-5502	terminal	_	_	
26-10	5503-5511	segments	_	_	
26-11	5512-5514	to	_	_	
26-12	5515-5525	respective	_	_	
26-13	5526-5539	complementary	_	_	
26-14	5540-5551	nucleotides	_	_	
26-15	5552-5554	in	_	_	
26-16	5555-5558	the	_	_	
26-17	5559-5565	target	_	_	
26-18	5566-5569	DNA	_	_	
26-19	5570-5578	sequence	_	_	
26-20	5579-5581	is	_	_	
26-21	5582-5583	a	_	_	
26-22	5584-5593	necessary	_	_	
26-23	5594-5606	precondition	_	_	
26-24	5607-5610	for	_	_	
26-25	5611-5614	the	_	_	
26-26	5615-5625	subsequent	_	_	
26-27	5626-5633	linkage	_	_	
26-28	5634-5636	of	_	_	
26-29	5637-5640	the	_	_	
26-30	5641-5644	two	_	_	
26-31	5645-5661	oligonucleotides	_	_	
26-32	5662-5664	to	_	_	
26-33	5665-5669	form	_	_	
26-34	5670-5671	a	_	_	
26-35	5672-5680	ligation	_	_	
26-36	5681-5688	product	_	_	
26-37	5688-5689	.	_	_	

#Text=It is only in this immediately adjacent arrangement that the two terminal nucleotides of the contiguous terminal segments of the oligonucleotides are close enough together to be joined by a ligating agent, e.g. a ligase.
27-1	5690-5692	It	_	_	
27-2	5693-5695	is	_	_	
27-3	5696-5700	only	_	_	
27-4	5701-5703	in	_	_	
27-5	5704-5708	this	_	_	
27-6	5709-5720	immediately	_	_	
27-7	5721-5729	adjacent	_	_	
27-8	5730-5741	arrangement	_	_	
27-9	5742-5746	that	_	_	
27-10	5747-5750	the	_	_	
27-11	5751-5754	two	_	_	
27-12	5755-5763	terminal	_	_	
27-13	5764-5775	nucleotides	_	_	
27-14	5776-5778	of	_	_	
27-15	5779-5782	the	_	_	
27-16	5783-5793	contiguous	_	_	
27-17	5794-5802	terminal	_	_	
27-18	5803-5811	segments	_	_	
27-19	5812-5814	of	_	_	
27-20	5815-5818	the	_	_	
27-21	5819-5835	oligonucleotides	_	_	
27-22	5836-5839	are	_	_	
27-23	5840-5845	close	_	_	
27-24	5846-5852	enough	_	_	
27-25	5853-5861	together	_	_	
27-26	5862-5864	to	_	_	
27-27	5865-5867	be	_	_	
27-28	5868-5874	joined	_	_	
27-29	5875-5877	by	_	_	
27-30	5878-5879	a	_	_	
27-31	5880-5888	ligating	_	_	
27-32	5889-5894	agent	_	_	
27-33	5894-5895	,	_	_	
27-34	5896-5899	e.g	_	_	
27-35	5899-5900	.	_	_	
27-36	5901-5902	a	_	_	
27-37	5903-5909	ligase	_	_	
27-38	5909-5910	.	_	_	

#Text=Should one of the two terminal nucleotides (or both) not be paired with a corresponding nucleotide in the DNA sequence to be investigated, ligation of the terminal nucleotides does not take place.
28-1	5911-5917	Should	_	_	
28-2	5918-5921	one	_	_	
28-3	5922-5924	of	_	_	
28-4	5925-5928	the	_	_	
28-5	5929-5932	two	_	_	
28-6	5933-5941	terminal	_	_	
28-7	5942-5953	nucleotides	_	_	
28-8	5954-5955	(	_	_	
28-9	5955-5957	or	_	_	
28-10	5958-5962	both	_	_	
28-11	5962-5963	)	_	_	
28-12	5964-5967	not	_	_	
28-13	5968-5970	be	_	_	
28-14	5971-5977	paired	_	_	
28-15	5978-5982	with	_	_	
28-16	5983-5984	a	_	_	
28-17	5985-5998	corresponding	_	_	
28-18	5999-6009	nucleotide	_	_	
28-19	6010-6012	in	_	_	
28-20	6013-6016	the	_	_	
28-21	6017-6020	DNA	_	_	
28-22	6021-6029	sequence	_	_	
28-23	6030-6032	to	_	_	
28-24	6033-6035	be	_	_	
28-25	6036-6048	investigated	_	_	
28-26	6048-6049	,	_	_	
28-27	6050-6058	ligation	_	_	
28-28	6059-6061	of	_	_	
28-29	6062-6065	the	_	_	
28-30	6066-6074	terminal	_	_	
28-31	6075-6086	nucleotides	_	_	
28-32	6087-6091	does	_	_	
28-33	6092-6095	not	_	_	
28-34	6096-6100	take	_	_	
28-35	6101-6106	place	_	_	
28-36	6106-6107	.	_	_	
